The primary objective of the imaging and Radiation Oncology Core (IROC) Group is to provide scientific and technical expertise for incorporation of appropriate, integrated Quality Assurance (QA) and image data management for both imaging and radiotherapy (RT) in applicable trials conducted by the National Clinical Trials Network (NCTN) Program. The leading QA centers; RPC, QARC, RTOG QA, ITC, ACRIN and CALGB/SWOG Imaging Core lab, in the current NCI Cooperative Group Program have joined together to form the IROC Group, administratively organized through the American College of Radiology (ACR) Clinical Research Center. The creation of IROC capitalizes on existing infrastructure and expertise at QA Centers currently providing services to the NCI Cooperative Groups. Work flows, processes and information systems currently in place will be further enhanced taking the best practices and standards in an integrated vision. The interdependencies between imaging and RT will be synergized in this QA Group eliminating duplication of services and optimizing towards efficient and effective workflows. A major strength of IROC will be the development of consistent standard operating procedures for all imaging and RT aspects of the NCTN and to facilitate a seamless flow of imaging and RT patient case datasets across the network. IROC's organizational structure allows the delivery of a broad array of imaging and RT QA services including Site Qualification; Trial Design Support; Credentialing; Data Management (Pre- and Post- Review); and Case Review. An information technology infrastructure will be developed that harmonizes IROC services, data collection, assessment and management for the NCTN Groups' clinical trials. IROC will implement programs that assure consistent high quality imaging and RT planning/delivery across the NCTN participating sites. IROC members will collaborate with the NCTN disease/modality committees within each Network Group to provide an optimal and effective imaging and RT core service. IROC will analyze QA data obtained prospectively/retrospectively to further advance QA science. IROC will manage all aspects of QA for NCTN trials that includes imaging and/or RT with the shared goal to achieve the best possible trial outcomes.
Today's cancer trials frequently require the use of imaging and/or RT to achieve the most effective treatment. Rigorous QA of these methodologies secures consistency across the participating sites by managing potential variability which would otherwise obscure true therapeutic outcomes.
|Glenn, Mallory C; Hernandez, Victor; Saez, Jordi et al. (2018) Treatment plan complexity does not predict IROC Houston anthropomorphic head and neck phantom performance. Phys Med Biol 63:205015|
|Videtic, Gregory M; Paulus, Rebecca; Singh, Anurag K et al. (2018) Long term follow-up on NRG Oncology RTOG 0915 (NCCTG N0927): A randomized phase II study comparing 2 stereotactic body radiation therapy schedules for medically inoperable patients with stage I peripheral non-small cell lung cancer. Int J Radiat Oncol Biol Phys :|
|Monroe, James I; Boparai, Karan; Xiao, Ying et al. (2018) NRG Oncology medical physicists' manpower survey quantifying support demands for multi-institutional clinical trials. Pract Radiat Oncol 8:324-331|
|Steinmann, Angela; Stafford, R Jason; Sawakuchi, Gabriel et al. (2018) Developing and characterizing MR/CT-visible materials used in QA phantoms for MRgRT systems. Med Phys 45:773-782|
|Men, Kuo; Boimel, Pamela; Janopaul-Naylor, James et al. (2018) Cascaded atrous convolution and spatial pyramid pooling for more accurate tumor target segmentation for rectal cancer radiotherapy. Phys Med Biol 63:185016|
|Michalski, Jeff M; Moughan, Jennifer; Purdy, James et al. (2018) Effect of Standard vs Dose-Escalated Radiation Therapy for Patients With Intermediate-Risk Prostate Cancer: The NRG Oncology RTOG 0126 Randomized Clinical Trial. JAMA Oncol 4:e180039|
|FitzGerald, Thomas J; Bishop-Jodoin, Maryann (2018) Hodgkin Lymphoma: Differences in Treatment Between Europe and the United States/North America: Evolving Trends in Protocol Therapy. Clin Med Insights Oncol 12:1179554918754885|
|Lewis, Dana J; Taylor, Paige A; Followill, David S et al. (2018) A New Anthropomorphic Pediatric Spine Phantom for Proton Therapy Clinical Trial Credentialing. Int J Part Ther 4:20-27|
|Lukka, Himanshu R; Pugh, Stephanie L; Bruner, Deborah W et al. (2018) Patient Reported Outcomes in NRG Oncology RTOG 0938, Evaluating Two Ultrahypofractionated Regimens for Prostate Cancer. Int J Radiat Oncol Biol Phys 102:287-295|
|Wright, Chadwick L; Binzel, Katherine; Zhang, Jun et al. (2017) Advanced Functional Tumor Imaging and Precision Nuclear Medicine Enabled by Digital PET Technologies. Contrast Media Mol Imaging 2017:5260305|
Showing the most recent 10 out of 87 publications